Immunological mechanisms operative in allergen-specific immunotherapy

被引:30
作者
Ebner, C [1 ]
机构
[1] Univ Vienna, Inst Gen & Expt Pathol, A-1010 Vienna, Austria
关键词
type I allergy; immunotherapy; specific; Th1; Th2; immune deviation; tolerance;
D O I
10.1159/000024168
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Specific immunotherapy (SIT) is the practice of administering increasing doses of allergen extracts to selected subjects suffering from IgE-mediated hypersensitivity, with the ultimate aim of ameliorating the symptoms associated with exposure to the causative allergen, The process is often called hyposensitization or desensitization because one consequence of the treatment is a reduction in sensitivity of the target organ after challenge with the relevant allergen. SIT has been practiced as treatment of type I allergy caused by inhalant allergens and Hymenoptera venoms for more than 80 years on an empirical basis. Today, numerous double-blind, placebo-controlled studies prove the therapeutic effect of SIT. However, the immunological mechanisms underlying successful specific immunotherapy have still not been completely elucidated, This review focuses on recent attempts to characterize the immunological events associated with SIT.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 62 条
  • [1] Role of interleukin 10 in specific immunotherapy
    Akdis, CA
    Blesken, T
    Akdis, M
    Wüthrich, B
    Blaser, K
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (01) : 98 - 106
  • [2] Epitope-specific T cell tolerance to phospholipase A(2) in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro
    Akdis, CA
    Akdis, M
    Blesken, T
    Wymann, D
    Alkan, SS
    Muller, U
    Blaser, K
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (07) : 1676 - 1683
  • [3] LOCAL NASAL IMMUNOTHERAPY FOR BIRCH ALLERGIC RHINITIS WITH EXTRACT IN POWDER FORM
    ANDRI, L
    SENNA, G
    ANDRI, G
    DAMA, A
    GIVANNI, S
    BETTELI, C
    DIMITRI, G
    FALAGIANI, P
    MEZZELANI, P
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 1995, 25 (11) : 1092 - 1099
  • [4] Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects
    Bellinghausen, I
    Metz, G
    Enk, AH
    Christmann, S
    Knop, J
    Saloga, J
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (05) : 1131 - 1139
  • [5] EVALUATION OF IMMUNOTHERAPY-INDUCED CHANGES IN SPECIFIC IGE, IGG AND IGG SUBCLASSES IN BIRCH POLLEN ALLERGIC PATIENTS BY MEANS OF IMMUNOBLOTTING - CORRELATION WITH CLINICAL-RESPONSE
    BIRKNER, T
    RUMPOLD, H
    JAROLIM, E
    EBNER, H
    BREITENBACH, M
    SKVARIL, F
    SCHEINER, O
    KRAFT, D
    [J]. ALLERGY, 1990, 45 (06) : 418 - 426
  • [6] RAPID HYMENOPTERA VENOM IMMUNOTHERAPY - COMPARATIVE SAFETY OF 3 PROTOCOLS
    BIRNBAUM, J
    CHARPIN, D
    VERVLOET, D
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 1993, 23 (03) : 226 - 230
  • [7] SPECIFIC IMMUNOTHERAPY IN ASTHMA - IS IT EFFECTIVE
    BOUSQUET, J
    MICHEL, FB
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 94 (01) : 1 - 11
  • [8] DOUBLE-BLIND, PLACEBO-CONTROLLED IMMUNOTHERAPY WITH MIXED GRASS-POLLEN ALLERGOIDS .1. RUSH IMMUNOTHERAPY WITH ALLERGOIDS AND STANDARDIZED ORCHARD GRASS-POLLEN EXTRACT
    BOUSQUET, J
    HEJJAOUI, A
    SKASSABROCIEK, W
    GUERIN, B
    MAASCH, HJ
    DHIVERT, H
    MICHEL, FB
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1987, 80 (04) : 591 - 598
  • [9] Bousquet J., 1998, Allergy (Copenhagen), V53, P1
  • [10] HUMAN PERIPHERAL-BLOOD BASOPHILS PRIMED BY INTERLEUKIN-3 (IL-3) PRODUCE IL-4 IN RESPONSE TO IMMUNOGLOBULIN-E-RECEPTOR STIMULATION
    BRUNNER, T
    HEUSSER, CH
    DAHINDEN, CA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (03) : 605 - 611